Anyone tried switching from RU to Pyrilutamide (KX-826) 1/12/2026
The conversation discusses switching from RU58841 to pyrilutamide for hair loss treatment, with users generally recommending staying on RU58841 if it is effective. RU58841 is sourced from GeneTherica, which ships worldwide.
View this post in the Community →
Similar Community Posts Join
5 / 5 resultscommunity Ru-58841 or KX-826 (Pyrilutamide)?
Exploring potential treatments for hair loss, with the focus being on comparing RU58841 and Pyrilutamide. Finasteride, Dutasteride, oral Minoxidil, microneedling, topical Minoxidil, Biotin, Zinc, Vitamin D and Nizoral are also discussed as part of a treatment stack.
community Kintor Has Completed Enrollment in Phase II Clinical Trial of KX-826 (Pyrilutamide) for Treatment of Male AGA Patients in the US
KX-826 (Pyrilutamide) being tested in the US for hair loss treatment and that they have found enough people to participate in phase II clinical trials. Other treatments discussed are Minoxidil, finasteride, and RU58841.
community Anyone used the 2% pyrilutamide / KX-826 from anagenica or anywhere else?
People are discussing hair loss treatments, including pyrilutamide, minoxidil, dutasteride, alfatradiol, and bimatoprost. Users share their experiences and side effects, noting that pyrilutamide is considered more effective and safer than RU58841.
community Anageninc no longer sell KX-826 (Pyrilutamide) due to receiving a cease and desist letter from Kintor :(
Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. Anageninc stopped selling KX-826 (Pyrilutamide) due to a cease and desist letter from Kintor, but this may indicate promising study results and a potential 2024 release.
community Has anyone used KX-826 as a MONOTHERAPY?
Exploring potential treatments for hair loss, such as Minoxidil, Finasteride, RU58841 and Pyrilutamide. The user is looking for feedback on whether KX-826 can be used successfully as a single therapy to stop the miniaturization process.
Related Research
6 / 6 results
research Nouvelles thérapeutiques dans la prise en charge de l’alopécie androgénétique
This thesis investigates the underlying mechanisms and treatment options for androgenetic alopecia, highlighting the molecular roles of androgens and genetic predispositions, and evaluates current and emerging therapies, such as PROTACs and Janus Kinase inhibitors, to enhance patient management.
research RU 58841, a new specific topical antiandrogen: A candidate of choice for the treatment of acne, androgenetic alopecia and hirsutism
This study found that the topically applied non-steroidal antiandrogen RU 58841 may reduce androgen-dependent skin conditions in a hamster model with minimal systemic effects.
research RU 58841-myristate–prodrug development for topical treatment of acne and androgenetic alopecia.
This study reports that RU 58841-myristate, a new antiandrogen prodrug formulated with solid lipid nanoparticles, shows potential for targeting hair follicles in preclinical laboratory settings.
research A controlled study of the effects of RU58841, a non-steroidal antiandrogen, on human hair production by balding scalp grafts maintained on testosterone-conditioned nude mice
This study found that the non-steroidal antiandrogen RU58841 increased hair growth rates and promoted hair cycle initiation in balding human scalp grafts on testosterone-conditioned nude mice, indicating a positive effect on hair growth.
research Alternative synthesis of the anti-baldness compound RU58841
A new, less toxic and more efficient method to create the anti-baldness compound RU58841 was developed in 2014.
research Dose-dependent and long term effects of RU58841 (androgen receptor blocker) on hair growth in the bald stumptailed Macaque.
In this study using a macaque model, RU58841 at a 5% concentration significantly increased hair density, thickness, and length in the frontal bald scalp over six months.